Karyopharm Therapeutics Inc.
KPTI
$4.64
-$0.06-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.73% | -21.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.73% | -21.25% | |||
| Cost of Revenue | 133.07% | -390.11% | |||
| Gross Profit | -104.24% | 10,214.38% | |||
| SG&A Expenses | 0.60% | -1.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.34% | -4.98% | |||
| Operating Income | -6.31% | -19.02% | |||
| Income Before Tax | 24.16% | 3.60% | |||
| Income Tax Expenses | 133.03% | -489.29% | |||
| Earnings from Continuing Operations | 23.78% | 4.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.78% | 4.03% | |||
| EBIT | -6.31% | -19.02% | |||
| EBITDA | -6.34% | -19.08% | |||
| EPS Basic | 24.48% | 4.69% | |||
| Normalized Basic EPS | 24.86% | 4.27% | |||
| EPS Diluted | 25.08% | 5.19% | |||
| Normalized Diluted EPS | 24.86% | 4.27% | |||
| Average Basic Shares Outstanding | 0.93% | 0.70% | |||
| Average Diluted Shares Outstanding | 0.93% | 0.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||